{"log_id": 8786191020674818742, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 8e-06, "average": 0.997263, "min": 0.992994}, "location": {"width": 98, "top": 169, "height": 30, "left": 96}, "words": "药理作用"}, {"probability": {"variance": 2.3e-05, "average": 0.996036, "min": 0.987831}, "location": {"width": 100, "top": 217, "height": 29, "left": 96}, "words": "作用机制"}, {"probability": {"variance": 0.000369, "average": 0.991981, "min": 0.906768}, "location": {"width": 920, "top": 255, "height": 41, "left": 145}, "words": "伊马替尼是一种小分子蛋白酪氨酸激酶抑制剂,可有效抑制Bcr-Abl酪氨酸激酶(TK)以"}, {"probability": {"variance": 0.000131, "average": 0.994266, "min": 0.942605}, "location": {"width": 969, "top": 303, "height": 42, "left": 98}, "words": "及下述几个TK受体的活性:Kit、通过c-Kit原癌基因编码的干细胞因子(SCF)受体、盘状"}, {"probability": {"variance": 0.002362, "average": 0.979705, "min": 0.710368}, "location": {"width": 966, "top": 351, "height": 43, "left": 98}, "words": "结构域受体(DDRl和DDR2)、集落刺激因子受体(CSF-1R)和血小板衍生生长因子受体a"}, {"probability": {"variance": 0.005755, "average": 0.974952, "min": 0.611696}, "location": {"width": 959, "top": 399, "height": 43, "left": 99}, "words": "和β( PDGFR-α和 PDGFR-β)。伊马替尼还可以抑制这些受体激酶激活后介导的细胞行为"}, {"probability": {"variance": 0.001519, "average": 0.985178, "min": 0.812053}, "location": {"width": 922, "top": 447, "height": 41, "left": 148}, "words": "伊马替尼在体内外均可在细胞水平上抑制Bcr-Abl酪氨酸激酶,能选择性抑制Bcr-Abl"}, {"probability": {"variance": 3.9e-05, "average": 0.997493, "min": 0.959892}, "location": {"width": 970, "top": 496, "height": 41, "left": 98}, "words": "阳性细胞系细胞、费城染色体阳性(Ph+)的慢性髓性白血病(CML)和急性淋巴细胞白血"}, {"probability": {"variance": 1e-06, "average": 0.999424, "min": 0.996827}, "location": {"width": 418, "top": 546, "height": 38, "left": 98}, "words": "病患者的新鲜细胞的增殖和诱导其凋亡"}, {"probability": {"variance": 0.000269, "average": 0.992832, "min": 0.923331}, "location": {"width": 919, "top": 590, "height": 39, "left": 149}, "words": "此外,伊马替尼还可抑制血小板衍化生长因子(PDGF)受体、干细胞因子(SCF),c-Kit"}, {"probability": {"variance": 3.3e-05, "average": 0.99725, "min": 0.969611}, "location": {"width": 730, "top": 638, "height": 43, "left": 101}, "words": "受体的酪氨酸激酶,从而抑制由PDGF和干细胞因子介导的细胞行为"}, {"probability": {"variance": 1e-06, "average": 0.999383, "min": 0.996354}, "location": {"width": 923, "top": 686, "height": 41, "left": 149}, "words": "有极少在临床产生耐药的报道,关于伊马替尼耐药的发生,初始耐药(从开始治疗即无"}, {"probability": {"variance": 0.000766, "average": 0.992615, "min": 0.818677}, "location": {"width": 970, "top": 734, "height": 42, "left": 103}, "words": "效)和继发耐药的区别是在整个伊马替尼的暴露进程中显示无效,Bcr-Abl酪氨酸激酶,在疾"}, {"probability": {"variance": 5e-06, "average": 0.998909, "min": 0.985674}, "location": {"width": 970, "top": 780, "height": 43, "left": 103}, "words": "病进程中增加,即为产生耐药的分子机制。在治疗的患者中产生耐药发生率很低,或者是没"}, {"probability": {"variance": 0, "average": 0.999588, "min": 0.997239}, "location": {"width": 752, "top": 830, "height": 40, "left": 102}, "words": "有按照要求服药。因此,治疗应尽早开始,同时剂量应严格按要求服用"}, {"probability": {"variance": 2e-06, "average": 0.999012, "min": 0.996806}, "location": {"width": 98, "top": 889, "height": 27, "left": 105}, "words": "毒理研究"}, {"probability": {"variance": 2e-06, "average": 0.999334, "min": 0.991076}, "location": {"width": 922, "top": 924, "height": 44, "left": 151}, "words": "在经伊马替尼长期治疗后,大鼠机会性感染的发生率增加,并且猴子体内通常被抑制的"}, {"probability": {"variance": 3e-06, "average": 0.998745, "min": 0.9943}, "location": {"width": 196, "top": 984, "height": 30, "left": 104}, "words": "疟疾感染病情加重"}, {"probability": {"variance": 0, "average": 0.999431, "min": 0.998316}, "location": {"width": 99, "top": 1033, "height": 28, "left": 105}, "words": "遗传毒性"}, {"probability": {"variance": 9.1e-05, "average": 0.996115, "min": 0.953109}, "location": {"width": 926, "top": 1070, "height": 41, "left": 153}, "words": "在一项体外细菌( Ames test)实验、一项体外哺乳动物细胞分析(小鼠淋巴瘤实验)和一项"}, {"probability": {"variance": 3e-06, "average": 0.998988, "min": 0.991432}, "location": {"width": 966, "top": 1117, "height": 42, "left": 109}, "words": "体内大鼠微核实验中,伊马替尼均没有显示任何基因毒特性。在一项体外哺乳细胞基因碎片"}, {"probability": {"variance": 0.003794, "average": 0.982219, "min": 0.731401}, "location": {"width": 944, "top": 1167, "height": 46, "left": 133}, "words": " clastogenicity)分析中(中国地鼠卵巢细胞染色体畸变),当代谢激活时,发现伊马替尼有"}, {"probability": {"variance": 3e-06, "average": 0.998902, "min": 0.993062}, "location": {"width": 970, "top": 1214, "height": 42, "left": 107}, "words": "阳性的基因毒作用。出现在成品中的因生产过程而产生的两个中间产物在Ames实验显示致"}, {"probability": {"variance": 1e-06, "average": 0.999282, "min": 0.996985}, "location": {"width": 605, "top": 1266, "height": 37, "left": 108}, "words": "突变性,其中一个中间产物在小鼠淋巴瘤实验中也呈阳性"}, {"probability": {"variance": 0, "average": 0.999642, "min": 0.999226}, "location": {"width": 99, "top": 1322, "height": 28, "left": 109}, "words": "生殖毒性"}, {"probability": {"variance": 8e-06, "average": 0.998249, "min": 0.985781}, "location": {"width": 894, "top": 1356, "height": 43, "left": 182}, "words": "项生殖力实验中,连续70天给予雄性大鼠60mg/kg(约相当于最大临床剂量800mg"}, {"probability": {"variance": 1e-05, "average": 0.998309, "min": 0.981486}, "location": {"width": 971, "top": 1405, "height": 42, "left": 110}, "words": "天),睾丸和副睾的重量减轻,同时精子的活动度降低。狗口服剂量>30mg/kg时,也观察到"}, {"probability": {"variance": 2e-06, "average": 0.999242, "min": 0.992385}, "location": {"width": 968, "top": 1452, "height": 43, "left": 111}, "words": "其精子的产生有轻度到中度降低。在一项雌性大鼠的生殖力研究中,交配和孕鼠的数量没有"}, {"probability": {"variance": 8e-06, "average": 0.998377, "min": 0.984497}, "location": {"width": 969, "top": 1499, "height": 46, "left": 110}, "words": "变化,但是在剂量60mg/kg而不是≤20mg/kg时,植入后胎儿的死亡明显增加,同时活胎数"}], "language": 3}